Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2022 Apr 29;29(5):3160-3170.
doi: 10.3390/curroncol29050257.

Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers-A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference

Karen Mulder  1 , Howard Lim  2 , Deepti Ravi  3 , Shahida Ahmed  4 , Bryan Brunet  5 , Janine Davies  2 , Corinne Doll  6 , Dorie-Anna Dueck  5 , Vallerie Gordon  4 , Pamela Hebbard  4 , Christina A Kim  4 , Duc Le  5 , Richard Lee-Ying  6 , John Paul McGhie  7 , Jason Park  4 , Daniel J Renouf  2 , Devin Schellenberg  8 , Ralph P W Wong  4 , Adnan Zaidi  5 , Shahid Ahmed  5
Affiliations
Guideline

Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers-A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference

Karen Mulder et al. Curr Oncol. .

Abstract

Gastric, esophageal and gastro-esophageal junction cancers are associated with inferior outcomes. For early-stage disease, perioperative chemotherapy or chemoradiation followed by surgery is the standard treatment. For most patients with advanced upper gastrointestinal tract cancers, platinum-based chemotherapy remains a standard treatment. Recently, several randomized clinical trials have demonstrated the benefit of immunotherapy involving checkpoint inhibitors alone or in combination with chemotherapy in patients with gastro-esophageal cancer and have changed the treatment landscape. The Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC), involving experts from four Western Canadian provinces, convened virtually on 16 June 2021 and developed the recommendations on the role of immunotherapy in patients with gastro-esophageal cancer.

Keywords: checkpoint inhibitors; esophageal cancer; gastroesophageal cancer; gastroesophageal junction cancer; immunotherapy; stomach cancer.

PubMed Disclaimer

Conflict of interest statement

Author Shahid Ahmed has served on advisory boards for Merck, BMS, Pfizer, Taiho and Roche. Author Karen Mulder has an advisory role for Pfizer Canada, Eisai Inc, Bayer Canada and has received clinical trial funding from Deciphera Pharmaceuticals, BluePrint Medicines and AstraZeneca. Author Janine Davies has clinical trials for BMS, Merck, MedImmune and Astellas Array BioPharma and is a consultant and a member of the advisory board for AstraZeneca, Eisai, Taiho and Amgen. Author Christina A. Kim received an unrelated research grant from Celgene Inc and an honorarium from Amgen. Author Howard Lim received honoraria from Merck, BMS, AstraZeneca, Eisai, Taiho, Roche, Amgen and Bayer for consultant work. Author Richard Lee-Ying had advisory roles for Eisai, Ipsen, AstraZeneca, Roche and Celgene. Author Daniel J. Renouf received unrelated research funding and honoraria from Bayer and Roche and travel funding and honoraria from Servier, Celgene, Taiho, Ipsen and AstraZeneca. Author Adnan Zaidi has provided consultant work for Merck and BMS. The remaining authors declare no conflicts of interest.

References

    1. Wong M.C.S., Huang J., Chan P.S.F., Choi P., Lao X.Q., Chan S.M., Teoh A., Liang P. Global Incidence and Mortality of Gastric Cancer, 1980–2018. JAMA Netw. Open. 2021;4:e2118457. doi: 10.1001/jamanetworkopen.2021.18457. - DOI - PMC - PubMed
    1. Huang J., Koulaouzidis A., Marlicz W., Lok V., Chu C., Ngai C., Zhang L., Chen P., Wang S., Yuan J., et al. Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries. Cancers. 2021;13:141. doi: 10.3390/cancers13010141. - DOI - PMC - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Al-Batran S.E., Homann N., Pauligk C., Goetze T.O., Meiler J., Kasper S., Kopp H.G., Mayer F., Haag G.M., Luley K., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluor-ouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet. 2019;393:1948–1957. - PubMed
    1. Eyck B.M., van Lanschot J.J.B., Hulshof M.C.C.M., van der Wilk B.J., Shapiro J., van Hagen P., van Berge Henegouwen M.I., Wijnhoven B.P.L., van Laarhoven H.W.M., Nieuwenhuijzen G.A.P., et al. Ten-Year Outcome of Neoadju-vant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J. Clin. Oncol. 2021;39:1995–2004. doi: 10.1200/JCO.20.03614. - DOI - PubMed

Publication types